Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma Academic Article uri icon

Overview

MeSH Major

  • Fluorodeoxyglucose F18
  • Hydrolases
  • Melanoma

abstract

  • These findings suggest that some unexpected pharmacologic properties of ADI preclude using (18)F-FDG to evaluate clinical response in melanoma and, more generally, argue for further studies to explore the use of PET tracers that target apoptotic pathway activation or cell death.

publication date

  • February 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.2967/jnumed.111.092973

PubMed ID

  • 22228793

Additional Document Info

start page

  • 281

end page

  • 6

volume

  • 53

number

  • 2